Objective: Affective disorder during pregnancy is a common condition requiring careful judgment to treat the depression while minimizing risk to the fetus. Fol lowing up on promising pilot trials, we studied the efficacy of light therapy.
A
ffective disorder during pregnancy is a common and severe condition. One in 10 pregnant women world wide suffers from depression with severe risks.
1,2 Depression during pregnancy is the strongest predictor of postpartum depression. 3 Depression is associated with a higher risk for complications during pregnancy, requiring more frequent medical attention. 4 Many studies have reported that preterm delivery and low birth weight are associated with depression (overview in Bennett et al, 1 Douki et al 2 ) . Endocrine dys regulation due to maternal stress affects the fetus and birth outcome. 5 Depressed pregnant women are at risk for inad equate nutrition; poor weight gain; increased use of nicotine, drugs, and alcohol; failure to obtain adequate prenatal care; and poor motherchild attachment. 6, 7 Furthermore, these wom en have a higher rate of surgical birth and vaginal operative delivery and their newborns have a higher rate of admission to neonatal intensive care. 1, 2 Their infants have a higher risk for cognitive, emotional, and behavioral disturbance. 6 Treatment of antepartum depression requires careful judgment to minimize risk to the fetus. 8 Pharmacologic treatment is an option, but all antidepressants cross the pla centa, and both practitioners and patients are concerned about possible teratogenicity, prenatal and perinatal adverse effects for the infant, as well as negative effects on longterm development. 2, 8, 9 Psychiatric medication use for depression in pregnancy may also pose a risk of fetal growth retardation and preterm delivery, 10 as well as withdrawal symptoms in the newborn, or pulmonary hypertension. 2, 8 The safety of pharmacologic treatment of depression in the pregnant woman is still con troversial, 8, 11, 12 with a lack of wellcontrolled studies. Many physicians and patients experience indecisiveness about the safety of antidepressant medication. 13, 14 Exploration of new approaches to treating the pregnant woman with major depression is therefore a priority. Interper sonal psychotherapy is a promising option (eg, Spinelli and Endicott 15 ) but not readily available in practice settings and impractical for women limited in support resources such as transportation and childcare. Socioeconomically disadvan taged childbearing and childrearing women are difficult to engage and retain in adequate treatment, and many are left to suffer together with their newborns.
Treatment of depression during pregnancy that is ef ficacious, reliable, safe, and with minor side effects is an urgent unmet clinical need. Light therapy is well established F ocus on Women's mental HealtH as the treatment of choice for seasonal affective disorder. Some promising data are available for nonseasonal major depression, 16 suggesting that light therapy may provide a nonpharmaceutical alternative in this vulnerable patient group of nonseasonally depressed pregnant women. Be cause rapid improvement (within a week) had been shown in seasonal affective disorder, early studies of nonseasonal major depression were mostly short in duration. Given that pharmacologic trials of major depression are conventionally 5 weeks or more, light therapy has had little chance to reveal efficacy, although metaanalyses of light therapy trials for nonseasonal depression are positive. [17] [18] [19] [20] There have been 2 pilot studies of light therapy in antepartum depression. A singleblind, nonrandomized trial administered 3-5 weeks of light therapy (10,000 lux light treatment for 60 minutes daily, shortly after subjects awak ened), and mean depression ratings improved by 50%. 21 A 5week randomized controlled trial comparing 7,000 lux with 500 lux designated as placebo, for 60 minutes daily, found improvements of 60% and 41%, respectively, 22 which pro vided the rationale for the present study. Five weeks appeared sufficient to attain benefit without terminating treatment before the appearance of significant group differences.
We hypothesized that morning bright light therapy (7,000 lux white) is an effective treatment for major depression during pregnancy compared with lowintensity placebo light therapy (70 lux red) when administered 60 minutes daily for 5 weeks.
METHOD

Participants
Women were recruited through referrals from the Uni versity Psychiatric Outpatient Department and Department of Obstetrics/Gynecology, University Hospital Basel, from practitioners in the northwest Basel area of Germanspeaking Switzerland, and directly through the media.
Of 100 women screened (telephone interview and a score ≥ 10 on the Edinburgh Postnatal Depression Scale 23 ), 70 met study entry criteria and came for assessment with the Structured Clinical Interview for DSM-IV Axis I Disorders 24 and a medical examination. The staff psychologist inter viewed participants at the Psychiatric Outpatient Department, University Hospital Basel, or at home, if required.
Inclusion criteria. The inclusion criteria were women who were 18-45 years of age; German speaking; medically healthy, with normal ocular function; 4 through 32 weeks gestation based on first trimester ultrasound; DSM-IV di agnosis of major depressive disorder; Structured Interview Guide for the Hamilton Depression Rating Scale (HDRS) 25 with Atypical Depression Supplement (SIGHADS) 26 * score *The SIGHADS, a rating scale for all subtypes of depression, contains the same items as used in the SIGHSAD, originally developed for evaluating winter depression (seasonal affective disorder). The sleep items have been reformulated to require specific timeofday estimates. The scoring structure remains the same. ≥ 20; and ability to provide informed consent. Although the majority were untreated, we included 4 women who had taken an antidepressant for more than 3 months without any improvement and kept medication constant during the study (paroxetine 10 mg, paroxetine 20 mg, fluoxetine 20 mg, and citalopram 20 mg). Exclusion criteria were DSM-IV diagnoses of bipolar I or II disorder, seasonal affective disorder, any psychotic episode, substance abuse within the last 6 months, primary anxiety disorder, recent history of suicide attempt (6 months), delayed sleep phase disorder or hypersomnia with habitual sleep onset later than 1 am or wakening later than 9 am, and obstetrical care or medications for medical disorders that might confound treatment results, fetal malformations, and intrauterine fetal death. After study completion, 6 patients reported that they had independently begun adjunct antidepressant medication during the trial and were excluded from the analyses.
Study Design
The study was a randomized, doubleblind, placebo controlled clinical trial, with a parallel design and duration of 5 weeks, testing the hypothesis that 60 min/d of 7,000 lux white light is an effective antidepressant compared with 70 lux red (placebo) light. The primary endpoint compared reduction in depressive symptoms as documented by the SIGHADS 29item version and the HDRS 17item subscale. Further analyses compared percentage improvement and categorical response, as well as additional observer and self report scales. The rationale for light treatment was explained to the patient, who also knew she had an equal chance of being assigned to differentcolored light boxes. She was in formed that standard psychiatric support, but not specific psychotherapy, also would be provided. The study design was approved by the Ethics Committee of the University of Basel, and patients signed informed consent. The study is registered at clinicaltrials.gov (identifier: NCT01043289).
Sample size was determined by the cited pilot trials in which a reduction in SIGHADS scores of 8 points (SD = 9), α = .05, would achieve a power of 0.81 with 17 subjects in each group. To obtain 34 complete observations with an an ticipated noncompletion rate of about 20%, we needed to enroll 42 women.
Light Therapy
Patients were asked to maintain their habitual bedtime and wakeup time and not to change it for study entry. Light treatment was planned to commence within 10 min utes of habitual wakeup time. The light box (Healthlight, SphereOne Inc, Silver Plume, Colorado, < 3 kg) could be conveniently transported and set up by pregnant women. During the 5week treatment period in their homes, sub jects sat in front of the light box daily for 60 minutes at a specified distance that provided an active dose of 7,000 lux white light (4.2 × 10 5 lux.min) or a placebo dose of 70 lux red light (3.0 × 10 3 lux.min). The active dose was found effec tive in the prior controlled treatment study. 22 The placebo
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Wirz-Justice et al 70 lux red light box was chosen because the earlier study using 500 lux white light indicated some efficacy. Red is far from the proposed active wavelengths in the blue part of the spectrum, 27 and the intensity is below the threshold for phaseshifting circadian rhythms (< 100 lux). 28 Dim red light < 100 lux has been suc cessfully used as placebo in several controlled light therapy trials. [29] [30] [31] Importantly, though, the patients perceived it as a credible light source according to their expectation ratings, and, therefore, it served as a plau sible placebo.
Randomization: maintaining the blind. An inde pendent staff member provided the nonblind research nurse computergenerated random assignments in blocks of 6. The light boxes were in identical, coded cartons to preserve the blind and kept in a separate area of the hospital. The nurse allocated the lamps to the patients after they had entered the study and was the only staff member thus informed. Patients were in structed not to discuss the nature of their light box with the rating interviewer and told we were investigating different wavelengths to find the optimum color. After receiving the light box, each subject rated the degree to which she believed she would improve after 5 weeks of light therapy on a scale of 0 (ineffective) to 5 (complete improvement). Expectation ratings (mean ± SD) were simi lar and moderately positive for bright light (3.3 ± 1.1, n = 16) and placebo light (3.3 ± 0.9, n = 11). They were asked to rate their judgment of light therapy after completing 5 weeks of treatment as well, and, again, these ratings were similar and positive (for the brightlight group, 3.4 ± 1.1, and, for the pla cebo group, 3.0 ± 1.1 [t 14 = 0.7, P = .49]), which indicates that the blind had been maintained.
Specific Instruments and Reliability Assessments
The baseline interview collected information on ethnic group, age, marital status, education level, parity, as well as previous depressive episodes. Instruments written and tested in English were professionally translated with blinded back translation.
The primary clinical outcome rating scale was the SIGH ADS. 26 The 29item scale incorporates the HDRS as well as assessment of atypical neurovegetative symptoms. This combined scale is the current benchmark for assessment of severity of depression in light therapy trials. Additional rating scales used to assess depth of depression were the MontgomeryAsberg Depression Rating Scale, 32 the Struc tured Interview Guide for the Hamilton Depression Rating ScaleSeasonal Affective Disorder Version-SelfRating Version (SIGHSADSR) 33 for selfratings, and the Beck Depression Inventory (BDI). 34 Safety was monitored with the selfreport version of the Systematic Assessment for Treatment Emergent Effects (SAFTEE), previously used to monitor side effects of light therapy. 35 Daily rating scales (mood and alertness ratings, sleep and light therapy logs) monitored compliance.
Statistical Analyses
The primary outcome measures were the SIGHADS and HDRS scores. Changes of rating scale scores over time (differences from baseline) were analyzed in the context of the general linear model. Differences from baseline of SIGHADS and HDRS scores at every time point were the dependent variables, time was the withinsubjects factor, and treatment (bright light vs placebo) was the between subjects factor. Baseline score of depression and gestational age at intervention start were included in the model. Post hoc power calculations were performed for the effect of the interaction between time and treatment on rating scale scores. We calculated the power of the withinbetween in teraction for repeated measures using the O'BrienShieh algorithm, as implemented in G*Power 3.0. 36 Finally, we ana lyzed categorical definitions of response (improvement ≥ 50%) and remission (improvement ≥ 50% to a final score ≤ 8) on both scales.
RESULTS
Clinical Response
Patient recruitment began in October 2004 and was com pleted in October 2008. Of 100 study applicants, 46 were enrolled and 34 completed the trial (12 dropouts). A further 6 were excluded from the analysis because of having begun adjunct therapy during the study and 1 because of poor com pliance (Figure 1) . Five of these 6 were in the placebo group. Thus, the analysis is based on 16 patients in the bright light group and 11 in the placebo group.
There were no significant differences between the bright and dimlight groups in sociodemographic or clinical factors (Table 1) . Light therapy logs (used to ascertain compliance) were similar in both groups. Table 2 summarizes the means of the main outcome vari ables of clinical efficacy, the SIGHADS and HDRS, at weekly intervals throughout 5 weeks' treatment. The Levene statistic affirmed homogeneity of the variance for the SIGHADS and HDRS. At baseline, the ratings were similar (P > .05). After 5 weeks, the SIGHADS score had dropped by 15.6 points in the brightlight group versus 11.9 points in the dimlight group; the HDRS score dropped by 11.2 points in bright light versus 7.4 points in dim light (Table 2A) .
The superiority of light over placebo was shown on both SIGHADS and HDRS when analyzing the weekly change from baseline (Table 2B) . A significant effect of the whole model on changes in severity of depression was found at week 5 (SIGHADS, R 2 = 0.251, F 3,23 = 3.91, P < .05; HDRS, R 2 = 0.338, F 3,23 = 5.42, P < .01), which indicates that the included factors significantly influenced, as a whole, the observed improvement in depression.
For the HDRS, there was a signifi cant interaction of treatment with time (F 4,92 = 2.91; P < .05), indicating that the decrease of depression severity did not fol low parallel slopes of time course ( Figure  2A) . The contrasting curve shapes show a monotonic weekly improvement for bright light versus unchanged status after week 2 for dim light. The strongest effects were observed with brightlight treatment, with greater improvement than placebo at week 5 (β = 0.419, t = 2.52, P < .05). Baseline de pression severity was a significant main effect (F 1,23 = 7.51, P < .05); higher sever ity led to better improvement (β = 0.498, t = 3.12, P < .01) without a time interaction. Gestational age showed a significant inter action with time (F 4,92 = 2.76, P < .05); the direction of effect suggests an inverse rela tionship with improvement, but univariate estimates were not significant at any time point.
Similarly, the SIGHADS showed an in teraction of treatment with time (F 4,92 = 2.87; P < .05), with greater effect under bright light. Baseline severity of depression and gestational age both showed trends toward a main effect at week 5 in a similar direc tion as found for HDRS (SIGHADS at baseline: F 1,23 = 4.04, P = .056; gestational age: F 1,23 = 3.60, P = .070).
The general linear model repeated measures analysis of variance was also performed, including as factors clinical variables that might affect the pattern of change of depressive ratings: age at onset of illness, number of previous depressive episodes, and du ration of current depressive episode. Among these, only the number of previous recurrences showed a significant inter action with time (HDRS: F 4,72 = 2.88, P = .029; SIGHADS: F 4,72 = 3.82, P = .007). The direction of the effect supports the hypothesis of better effects in more severe patients: the more previous depressive episodes, the better the improve ment. Adding this factor to treatment, baseline severity of depression, and pregnancy week did not significantly change the overall goodnessoffit of the model and confirmed the significant time × treatment interaction (HDRS: F 4,88 = 3.00, P = .023; SIGHADS: 
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Wirz-Justice et al between responders and nonresponders (items: depression, work and activities, feelings of guilt, psychic anxiety, somatic anxiety, social with drawal, and fatigability/lack of energy). 37 Examination of daily logs showed that sleep was not disrupted by light treatment, although there was individual variability in wakeup time and/or interval between wakeup and light ther apy. No patient showed a sudden switch out of depression, as might be found with sleep deprivation 16 -rather, improvement was grad ual over the 5 weeks' treatment.
The ancillary rating scales all revealed score reductions from baseline to week 5. Fewer pa tients completed these ratings, which lessens the likelihood of finding significant differences. After 5 weeks of brightlight treatment, pa tients in the brightlight group tended to have lower MontgomeryAsberg Depression Rating Scale scores than patients in the placebo group (t 20 = −1.55, P = .068) ( Table 4) . Selfratings also improved with time, but neither BDI nor SIGHSADSR differed significantly between groups after 5 weeks of treat ment (Table 4) .
Only 4 patients were taking antidepressants (and had not responded to them). They were in the brightlight group, and all improved.
Among study completers, 6 patients decided to start a drug treatment, and 5 of them were receiving placebo light. The decision to combine antidepressant drugs was then mar ginally higher in the placebo group (χ 2 1 = 3.57, P = .059). Although no patients fulfilled criteria for seasonal affec tive disorder, the screening questionnaire for sea sonality 38 yielded 8 patients with seasonal affective disorderequivalent symptoms (2 in the brightlight group) and 1 with subsyndromal seasonal affective disorder. However, there was no correlation between clinical improvement and degree of seasonality. There were also no differences in the final scores of the depression scales between the seasonal and nonseasonal subjects. In addition, we checked the season in which patients were treated with light (slightly more in the winter months). Again, there was no correlation between season of treatment and response.
Using the SAFTEE questionnaire weekly, we found no clinically meaningful side effects at any time point. All women gave birth without perinatal complication.
DISCUSSION
Although both groups showed similar baseline severity, brightlight therapy showed greater reduction in depression ratings than placebo dim light after 5 weeks of treatment. A difference of 4 points in the HDRS at week 5 is impressive for an antidepressant trial-the majority of placebocontrolled drug studies show a difference of about 2 points with far larger sample size. 39 A similar effect was seen for the expanded Percentage improvement showed the significant ad vantage of bright light across time on the SIGHADS (F 4,100 = 17.88, P < .001), with a significant interaction (F 4,100 = 2.72, P < .05). The HDRS also showed improvement over time (F 4,100 = 12.06, P < .001) but only a trend for inter action (F 4,100 = 1.89, P = .118).
A paired t test comparison of baseline week 0 with week 5 yielded significance for bright white light over placebo for HDRS values (t 25 = 1.97, P 1sided < .05) but not for the SIGH ADS. The percentage improvement at week 5 was significant for both SIGHADS (57.5% ± 4.6% vs 41.2% ± 8.8%; t 25 = 1.78, P 1sided < .05) and HDRS (63.9% ± 5.1% vs 37.5% ± 10.7%; t 25 = 2.45, P 1sided < .05). Categorical analyses ( Figure 2B , Table 3 ) also showed the superiority of bright light, with higher response rate on both scales and higher remission rate on the HDRS.
An itembyitem validation of the German SIGHADS was carried out. 37 Many somatic symptoms of depression in pregnant women improved with light therapy (none re lated to sleep and appetite). We therefore extracted a short, 7item scale for future clinical use that could differentiate SIGHADS scale, which includes 8 atypical neurovegeta tive items, and the 4 last items on the 21item HDRS. Even though the SIGHADS is weighted toward somatic factors prevalent in pregnancy independent of depressive symp toms, it provided results similar to the HDRS. 37 The effect sizes of 0.78 for the HDRS and 0.82 for the SIGHADS are large, 40 yet they may indeed be conservative: 5 of the 6 pa tients who began antidepressant drug treatment during the trial were in the placebo group, which suggests that placebo produced less benefit than bright light, leading subjects to seek additional treatment off protocol.
The decrease of depression severity did not follow paral lel slopes of time course for bright light and placebo. This pattern of treatmentemergent medicationplacebo differ ence is closely similar to that observed with antidepressant drugs. Clinical trials that explore the hypothesized superi ority of antidepressant drugs over placebo have consistently affirmed that no difference can be expected between the treatments during the first 2 weeks, as conclusively confirmed by metaanalysis, 41 and, recently, that placebocontrolled antidepressant clinical trials do not yield significant dif ferences at less than 4 weeks' duration. 42 The similarities between the time course of the effects of light therapy and of pharmacologic antidepressant treatments, as reported in independent studies, increase the confidence in our results, which merit replication in an independent, larger sample, as well as consideration of optimum light intensity and dura tion of treatment.
Given the limited treatment options for pregnant women with depression, the potential benefit of light therapy is promising. The side effect profile of light therapy is attrac tive. Although as yet there are no data to verify that light therapy incurs minimal risk to the fetus, a simple analogy can be made. One hour of light therapy provides light exposure similar to 1 hour of outdoor light. Indeed, in patients with winter depression, a regular 1hour morning walk outdoors provides therapeutic effect similar to a light box. 43 At typical daily exposures, natural light is safe for the eyes. Obstacles to prescribing outdoor treatment, of course, include variable weather conditions and seasonal light availability.
In terms of ophthalmologic safety, patients with retinal or other eye disorders should consult an ophthalmologist before using light therapy and periodically thereafter. Long term studies in seasonal affective disorder patients have not found any clinically significant emergence or exacerbation of ocular symptoms. 44 Lithium reduces light sensitivity, which may require longer exposure duration for clinical response, but its effect on retinal sensitivity is reversible. 45 There are no ophthalmologic studies investigating interaction with antidepressant drugs. Clinical trials of light plus medication suggest a potentiation of the therapeutic effect.
31, 46 None of our patients used photosensitizing psychotropics.
There were no switches into hypomania in our study. There is a potential for light to induce a switch in patients with bipolar disorder, but it is low if the patients are on pro phylactic treatment. 47 Moreover, when deciding to choose early morning light therapy versus antidepressant drug treat ment in patients with a personal or family history of bipolar illness, it should be noted that the most powerful chrono therapeutic interventions have been associated with a risk of manic switches not exceeding 10% versus a risk of develop ment of treatmentemergent mania in roughly onequarter of bipolar patients administered antidepressant drugs. 47, 48 The light box used in this study has been tested in a several clinical trials and conforms to stringent standards, such as adequate size for illuminating a broad visual field, lighting from above to avoid glare, and ultraviolet screening. Many light therapy devices on the market have not under gone any clinical trials, so generalizations cannot be made, except in the case of similar designs (but not for pocket lighting devices nor for blueenhanced ones).
The strengths of this study were the stringent entry and response criteria and the placebocontrolled protocol; a limitation was the number of patients. In order to optimize effects, treatment duration may need to be longer than the 5 weeks studied here. The earlier placebocontrolled pilot study found only a trend toward better improvement with bright light at week 5, which became significant after 10 weeks. 22 Women beyond the 36th week of gestation may thus not derive immediate benefit during pregnancy. However, continued treatment postpartum has promise, given that antepartum depression predicts postpartum depression. 3 Several patients have elected this option following comple tion of the protocol, with success.
Although there are many studies of light therapy for non seasonal depression, none have been without antidepressant drug treatment, and too many protocol differences exist to make a confident comparison.
In summary, light therapy is perceived as "natural" and therefore appeals to pregnant women, since most of them 
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